ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2645

Pathological Roles Of The Anti-Oxidative Enzyme Peroxiredoxin 2 In Patients With Kawasaki Disease

Rie Karasawa1, Toshiko Sato1, Mayumi Tamaki1, Mikiya Fujieda2, Kazuhide Ohta3 and Kazuo Yudoh1, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2Department of Pediatrics, Kochi Medical School, Nankoku, Japan, 3Department of Pediatrics, Kanazawa Medical Center, Kanazawa, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, biomarkers and proteomics, Kawasaki disease

  • Tweet
  • Email
  • Print
Session Information

Title: ACR Plenary Session III: Discovery 2013

Session Type: Plenary Sessions

Background/Purpose: Anti-endothelial cell antibodies (AECA) are autoantibodies that are detected frequently in vasculitis caused by, for example, Kawasaki disease (KD). However, AECA target molecules have been poorly identified, which hampers our understanding of the roles of AECA. We aimed to detect target proteins of AECA comprehensively by proteomics and investigate their clinical importance in patients with KD.

Methods: We separated proteins extracted from human umbilical vein endothelial cells (HUVECs) and HeLa cells by 2-dimensional electrophoresis and transferred them onto membranes. Antigens that were positive only in the HUVEC samples but not in the HeLa cell samples were detected by western blot, using serum samples from patients with vasculitis. Next, we identified the detected proteins by peptide mass finger-printing and characterized their antigenicity by preparing recombinant antigens and antibodies to them. Furthermore, we investigated the frequency, clinical significance, and pathological roles of AECA against individual identified target autoantigens.

Results: We identified 63 proteins, one of which was peroxiredoxin 2 (Prx2), an anti-oxidative enzyme. Using immunocytochemistry, antibodies against Prx2 were found to bind to the cell surface of live HUVECs. IgG antibodies to Prx2 were detected in 60% (18/30) of the patients with KD, but not in healthy controls. Furthermore, IgG antibodies to Prx2 were detected in all tested KD patients with coronary artery lesions. Stimulating endothelial cells (ECs) with anti-Prx2 antibodies resulted in increased H2O2levels in the cell lysates. The anti-Prx2 antibodies also increased various inflammatory cytokine secretions significantly; in particular, IL-6 in HUVECs and G-CSF in human coronary artery ECs. In addition, anti-Prx2 antibodies induced the increased expression of adhesion molecules, such as E-selectin and ICAM-1, on ECs. EC ELISA indicated that Prx2 proteins were released from ECs stimulated by inflammatory cytokines. By themselves, Prx2 proteins induced various inflammatory cytokine secretions, such as IL-6, IL-8, TNF-α and GM-CSF, from ECs, and the expression of adhesion molecules such as E-selectin and ICAM-1 on ECs. Interestingly, these effects of Prx2 proteins were enhanced significantly by the appearance of anti-Prx2 antibodies and were inhibited significantly by blocking Toll-like receptor 4 (TLR4) signaling with a TLR4-specific inhibitory peptide. Clinically, the duration of fever (>37.5°C) in KD patients was significantly longer in the anti-Prx2–positive group than in the anti-Prx2–negative group. There was no significant difference in inflammatory markers such as white blood cell counts and C-reactive protein between both groups.

Conclusion: IgG antibodies to Prx2 are expected to be useful markers for KD. Expression of endothelial adhesion molecules and inflammatory cytokine production are induced by the binding of anti-Prx2 antibodies to Prx2 proteins on ECs, and by the activation of TLR4 by extracellular Prx2 proteins, which could result in endothelial injury. Furthermore, anti-Prx2 antibodies may cause endothelial injury by inhibiting the anti-oxidative activity of intracellular Prx2 proteins.


Disclosure:

R. Karasawa,
None;

T. Sato,
None;

M. Tamaki,
None;

M. Fujieda,
None;

K. Ohta,
None;

K. Yudoh,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pathological-roles-of-the-anti-oxidative-enzyme-peroxiredoxin-2-in-patients-with-kawasaki-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology